{"id":746466,"date":"2023-04-11T07:03:15","date_gmt":"2023-04-11T11:03:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/"},"modified":"2023-04-11T07:03:15","modified_gmt":"2023-04-11T11:03:15","slug":"verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/","title":{"rendered":"Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WEST CHESTER, Pa., April  11, 2023  (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President and CEO, will present at the 22<sup>nd<\/sup> Annual Needham Virtual Healthcare Conference, which is being held from April 17-20, 2023.<\/p>\n<p>\n        <strong>Event details<\/strong>:<\/p>\n<p>Date: Monday, April 17, 2023<\/p>\n<p>Time: 2:15 \u2013 2:55 PM ET (Fireside Chat)<\/p>\n<p>Location: Virtual<\/p>\n<p>Participants may access a live webcast of the event through the following link:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RVNdEJ7b8tZ28InTilvVK670oM9wXIfLSMSa5ApY33UwucuZga120xqXlya1go9dGdjTsieI_gncSAD5Ogcy3c2PesGx7oUS69DyUaSSJOLrMfEC3FamTQctScZnGEEucdFHyXr0ArVCiXoRm4ar0OjvvETwUmCHiGoN6xfrxR4=\" rel=\"nofollow noopener\" target=\"_blank\"><strong>https:\/\/wsw.com\/webcast\/needham129\/vrca\/2250664<\/strong><\/a><\/p>\n<p>The webcast can also be accessed in the Investors\/Presentations &amp; Events section of the Verrica website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DMAZJSy3KHaPDAqNi8zu2Vw4d2BIVUCnoKvRkuyO-FpzfRxo-Y-_ouDsYJUuf2lQ3zfGfVV3cdPpt-GwGe-9Ow==\" rel=\"nofollow noopener\" target=\"_blank\">www.verrica.com<\/a>. The webcast replay will be available shortly after conclusion of the event for 30 days.<\/p>\n<p>\n        <strong>About Verrica Pharmaceuticals Inc.<\/strong>\n      <\/p>\n<p>Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica\u2019s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP- 315 (formerly LTX-315 and VP-LTX-315) for dermatologic oncology conditions. For more information, visit www.verrica.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cwill,\u201d and similar expressions, and are based on Verrica\u2019s current beliefs and expectations. These forward-looking statements include expectations regarding the approval of VP-102 for the treatment of molluscum, the timing of clinical trial completion for VP-315 and Verrica\u2019s cash and cash equivalents being sufficient to support planned operations into the first quarter of 2024. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica\u2019s reliance on third parties over which it may not always have full control, uncertainties related to the COVID-19 pandemic and other risks and uncertainties that are described in Verrica\u2019s Annual Report on Form 10-K for the year ended December 31, 2022 and other filings Verrica makes with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>FOR MORE INFORMATION, PLEASE CONTACT:<\/strong>\n      <\/p>\n<p>Investors:<\/p>\n<p>\n        <strong>Terry Kohler<\/strong><br \/>\n        <br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SMd9yEzrFd-bdl1q2fjc4tptHlHqMKEJWyqeriIkxyueWfr087F8JVcLHX2C38pOU9zLk84N4c_S0o5T-jma0FYGB5e69FLNzrCoB3C7aaM=\" rel=\"nofollow noopener\" target=\"_blank\">tkohler@verrica.com<\/a><\/p>\n<p>\n        <strong>Kevin Gardner<\/strong><br \/>\n        <br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Mb7pcTsC1lUkq_qZCH3fFr7twjF587-Y1h0-CRWQYpgObESJkJkiUHlIN0W5uX7daHqJRddnLf_A6L9cmcBjyT_nQsiRraLldRjq7VoDfMDz5JpsTYbwGN1OjOGUm_9u\" rel=\"nofollow noopener\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Chris Calabrese<\/strong><br \/>\n        <br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bn9hoII06PwNzVs7ttFKrl48wp3jfM46siDof6zNhioiFz6jOmIQ1cryRVDTfjdI-cl7G5ilYhU1eys1Gd-GuGvDTy0VRMydxW4MoDFM-0HutCW2lUeshtf9wEClHVQK\" rel=\"nofollow noopener\" target=\"_blank\">ccalabrese@lifesciadvisors.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTE5MCM1NTE5MDk2IzIxMjA3NDg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjEyYWFjZTMtNTI5NC00NDY1LWE2NTMtMzA0ZjE5NmU5YTJiLTExMzIzMTk=\/tiny\/Verrica-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WEST CHESTER, Pa., April 11, 2023 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President and CEO, will present at the 22nd Annual Needham Virtual Healthcare Conference, which is being held from April 17-20, 2023. Event details: Date: Monday, April 17, 2023 Time: 2:15 \u2013 2:55 PM ET (Fireside Chat) Location: Virtual Participants may access a live webcast of the event through the following link:https:\/\/wsw.com\/webcast\/needham129\/vrca\/2250664 The webcast can also be accessed in the Investors\/Presentations &amp; Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days. About Verrica Pharmaceuticals Inc. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-746466","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WEST CHESTER, Pa., April 11, 2023 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President and CEO, will present at the 22nd Annual Needham Virtual Healthcare Conference, which is being held from April 17-20, 2023. Event details: Date: Monday, April 17, 2023 Time: 2:15 \u2013 2:55 PM ET (Fireside Chat) Location: Virtual Participants may access a live webcast of the event through the following link:https:\/\/wsw.com\/webcast\/needham129\/vrca\/2250664 The webcast can also be accessed in the Investors\/Presentations &amp; Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days. About Verrica Pharmaceuticals Inc. &hellip; Continue reading &quot;Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T11:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTE5MCM1NTE5MDk2IzIxMjA3NDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference\",\"datePublished\":\"2023-04-11T11:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\"},\"wordCount\":504,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNTE5MCM1NTE5MDk2IzIxMjA3NDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\",\"name\":\"Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNTE5MCM1NTE5MDk2IzIxMjA3NDg=\",\"datePublished\":\"2023-04-11T11:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNTE5MCM1NTE5MDk2IzIxMjA3NDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNTE5MCM1NTE5MDk2IzIxMjA3NDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk","og_description":"WEST CHESTER, Pa., April 11, 2023 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President and CEO, will present at the 22nd Annual Needham Virtual Healthcare Conference, which is being held from April 17-20, 2023. Event details: Date: Monday, April 17, 2023 Time: 2:15 \u2013 2:55 PM ET (Fireside Chat) Location: Virtual Participants may access a live webcast of the event through the following link:https:\/\/wsw.com\/webcast\/needham129\/vrca\/2250664 The webcast can also be accessed in the Investors\/Presentations &amp; Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days. About Verrica Pharmaceuticals Inc. &hellip; Continue reading \"Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-11T11:03:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTE5MCM1NTE5MDk2IzIxMjA3NDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference","datePublished":"2023-04-11T11:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/"},"wordCount":504,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTE5MCM1NTE5MDk2IzIxMjA3NDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/","name":"Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTE5MCM1NTE5MDk2IzIxMjA3NDg=","datePublished":"2023-04-11T11:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTE5MCM1NTE5MDk2IzIxMjA3NDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNTE5MCM1NTE5MDk2IzIxMjA3NDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-announces-presentation-at-the-22nd-annual-needham-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746466","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=746466"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746466\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=746466"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=746466"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=746466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}